Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen et al.,
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,
medRxiv doi:10.1101/2020.03.22.20040758 (Preprint)
62 patients. RCT showing significantly faster recovery with HCQ. 13% progressed to severe cases in the control group, versus 0% for the treatment group. Significant improvement seen in pneumonia on chest CT for 61% of treated patients and 16% of control patients.
risk of no improvement in pneumonia at day 6, 57.0% lower, RR 0.43, p = 0.04, treatment 6 of 31 (19.4%), control 14 of 31 (45.2%), NNT 3.9.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Chen et al., 31 Mar 2020, Randomized Controlled Trial, China, preprint, 9 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.03.22.20040758; this version posted April 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Zhaowei Chen1, , Jijia Hu1, , Zongwei Zhang1, Shan Jiang2, Shoumeng Han3, Dandan Yan4, Ruhong
Zhuang5, Ben Hu 6 and Zhan Zhang7,*
1
Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
2
Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
3
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
4
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
5
Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
6
CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety
Mega-Science, Chinese Academy of Sciences, Wuhan 430060, China.
7
Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan University,
Wuhan 430060, China.
Zhaowei Chen and Jijia Hu contributed equally to this work.
*
Corresponding author:
Zhan Zhang, Department II of Respiratory Disease and Intensive Care, Renmin Hospital of Wuhan
University, Wuhan 430060, China. Email: doctorzhang2003@163.com
Abstract
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro.
However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy
of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.
Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were
diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in
a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d)
treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were
assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.
Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were
female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the
control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.03.22.20040758; this version posted April 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion
of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the
control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the
control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group.
Significance: Among..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit